HRS-4642
Phase 1Active 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced KRAS G12D Mutant Solid Tumors
Conditions
Advanced KRAS G12D Mutant Solid Tumors
Trial Timeline
Sep 21, 2022 → Dec 30, 2025
NCT ID
NCT05533463About HRS-4642
HRS-4642 is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Advanced KRAS G12D Mutant Solid Tumors. The current trial status is active. This product is registered under clinical trial identifier NCT05533463. Target conditions include Advanced KRAS G12D Mutant Solid Tumors.
What happened to similar drugs?
16 of 20 similar drugs in Advanced KRAS G12D Mutant Solid Tumors were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
6
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06520488 | Phase 1/2 | Recruiting |
| NCT05533463 | Phase 1 | Active |
Competing Products
20 competing products in Advanced KRAS G12D Mutant Solid Tumors